Based on the foregoing, the effectiveness in the treatment of doxycycline of changing the type of insulin from porcine insulin to human insulin is understandable: antibodies produced for porcine insulin did not interact with human insulin and their insulin-blocking effect on adipocytes was removed. Currently, lipoatrophy at the injection sites of insulin is not observed, but if they did occur, then, I believe, it would be effective to replace human insulin with analogues of human insulin and, vice versa, depending on which insulin developed lipoatrophy.
However, the problem of local reactions to the insulin preparation did not disappear.
The method of treatment is to inject insulin into the deep layers of the subcutaneous fat so that the inflammation does not appear on the skin, which is of the greatest concern. These reactions do not affect the effect of treatment, and in my practice they have never become a reason for changing the drug, i.e. reactions are expressed rather moderately.
